Published sequences do not support transfer of oseltamivir resistance mutations from avian to human influenza A virus strains
© Norberg et al.; licensee BioMed Central. 2015
Received: 12 August 2014
Accepted: 26 February 2015
Published: 28 March 2015
Tamiflu (oseltamivir phosphate ester, OE) is a widely used antiviral active against influenza A virus. Its active metabolite, oseltamivir carboxylate (OC), is chemically stable and secreted into wastewater treatment plants. OC contamination of natural habitats of waterfowl might induce OC resistance in influenza viruses persistently infecting waterfowl, and lead to transfer of OC-resistance from avian to human influenza. The aim of this study was to evaluate whether such has occurred.
A genomics approach including phylogenetic analysis and probability calculations for homologous recombination was applied on altogether 19,755 neuraminidase (N1 and N2) genes from virus sampled in humans and birds, with and without resistance mutations.
No evidence for transfer of OE resistance mutations from avian to human N genes was obtained, and events suggesting recombination between human and avian influenza virus variants could not be traced in the sequence material studied.
The results indicate that resistance in influenza viruses infecting humans is due to the selection pressure posed by the global OE administration in humans rather than transfer from avian influenza A virus strains carrying mutations induced by environmental exposure to OC.
KeywordsInfluenza A Avian influenza Tamiflu Oseltamivir resistance Resistance mutations
Tamiflu (oseltamivir phosphate ester, OE) is recommended by the WHO as a first line defense during influenza pandemic situations . The active metabolite, oseltamivir carboxylate (OC) is secreted via urine or feces  and degraded only scarcely by wastewater treatment plants, which might lead to contamination of aquatic ecosystems hosting waterfowl . Since influenza virus infections are persistent in waterfowl it has been postulated that presence of OC in the natural habitats of such birds could induce OC resistance among the influenza virus strains that colonize waterfowl [4,5]. This apprehension has been supported by field studies describing OC resistance mutations in influenza A virus isolated from wild birds , and experimentally by demonstrating rapid development of OC-resistant virus in influenza A virus-infected mallards that were kept in artificial, OC-containing environments . This has raised concerns that OC-resistance mutations might be transferred to influenza A viruses that circulate among humans, thereby compromising the use of OE . It is therefore important to assess, firstly, the risks for transfer of OC resistance mutations that emerge in avian influenza virus into influenza virus spreading in the human population, and, secondly, the possible influence of this phenomenon on treatment efficiency.
The influenza virus neuraminidase (N) is the molecular target for OE/OC and, hence, the viral N genes are the major carriers of resistance mutations (Reviewed in ). Although zoonotic transfer of avian influenza A virus to man occurs, mostly involving H5N1, H7N7, H7N2, H7N3, and H7N9 [10,11], this usually represents a dead end because further man-to-man transfer is rare. This does, however, not per se preclude the possibility that OC resistant mutations generated in avian influenza viruses could be transferred to human viruses (here the term “human influenza virus” denotes virus variants with capacity to spread in the human population) with or without involvement of swine or other animals  considered as “mixing vessels” for new pandemic influenza virus.
The probability of future genetic resistance transfer from avian influenza virus to viruses circulating in the human population may be assessed by evaluating past interactions and exchange of genetic material between these viruses. Thus, if transfer of resistance mutations from avian influenza virus to human influenza virus has occurred, this would have resulted in avian influenza virus sequence imprints in the N gene, some of which should appear in published human OC-resistant sequences. To check for this possibility we analyzed a large number of N1 and N2 gene sequences of human and avian influenza A viruses representing both OC-resistant and wild-type strains.
Avian and human influenza virus N1 and N2 genes studied
The influenza virus N1 and N2 genes discussed below were derived from specimens taken from humans (human sources) or from birds (avian sources). Altogether 10,351 N1 genes from human sources and 2,062 N1 genes from avian sources were analyzed, of which 107 genes from human sources and four genes from an avian sources contained the OE resistance mutant H274Y (designations of resistance mutations as recommended by Ferraris and Lina ), considered to be of relevance for OE resistance in human subjects . In addition, altogether 7,342 N2 sequences of human (n = 5,866) or avian (n = 1,476) sources were analyzed, of which six human sources and one avian source genes contained the R292K mutation, considered to be of relevance for OE resistance in human subjects. The sequences analyzed were derived from strains collected between year 1933 and 2012 (more than 90% later than 2000), and sequence data were obtained from the GISAID (Global Initiative on Sharing Avian Influenza Data) EpiFlu™ Database. The search parameters were as follows for respective type A influenza virus: Host: Human and Avian, Location: all, Full genome: yes, Required Segments: HA and NA. Detailed information about all strains harboring any of the above mentioned resistance mutations are listed in Additional file 1: Table S1, Additional file 2: Table S2, Additional file 3: Table S3, Additional file 4: Table S4, Additional file 5: Table S5, Additional file 6: Table S6.
Phylogenetic and recombination analysis
The un-rooted phylogenetic trees were constructed using the dnadist and neighbor joining programs included in the phylip package , using default settings. The search for homologous recombination was carried out by using the phi-test , and the methods RDP, GENECONV, Bootscan, MaxChi, Chimaera, SiScan, 3Seq, and LARD included in the RDP package .
In addition to H274Y or R292K, we also analyzed the whole set of 12,413 N1 and 7,342 N2 sequences for the presence of other resistance mutations (I117V, E119V, D198N, I222V, N294S and I314V). In total, any of these additional resistance mutations were identified in 137 N1 sequences (48 avian, 89 human) and 103 N2 sequences (31 avian, 72 human), but in none of these did we observe signs of transfer of resistance between human and avian strains by reassortment or recombination, as shown in Additional file 7: Figure S1 and Additional file 8: Figure S2.
The recent demonstration of intra-segmental homologous recombination in influenza A virus  has raised the question whether the OE resistance mutations could have been transferred from avian N genes to human N genes via intragenic recombination between human and avian N genes. This would result in chimeric N genes in H1N1 or H3N2 virus with avian as well as human sequence elements. We searched for homologous recombination between avian and human N1 or N2 genes using the phi-test and methods included in the RDP package, i.e., the methods RDP, GENECONV, Bootscan, MaxChi, Chimaera, SiScan, 3Seq, and LARD. The analysis was performed on all large datasets included in this study. No sign of intra-segmental homologous recombination between human and avian N1 or N2 genes was observed by any of the applied methods (p = 0.937 according to the phi test). To avoid inference of multiple testing owing to the large number of similar strains without resistance mutations, we also performed all tests on smaller datasets in parallel. These datasets contained only the consensus strains of all major clades (marked as A to D in Figure 1A and B in Figure 2), and the strains containing the resistance markers. Nor in these datasets could we find any sign of intra-segmental homologous recombination between human and avian N1 or N2 genes resulting in transfer of resistance mutations.
The present study, based on analysis of more than 19,700 complete N1 and N2 sequences in specimens from humans infected with H1N1 or H3N2 virus, shows that transfer of avian N genes to human influenza virus via re-assortment or intra-segmental homologous recombination is a rare event, irrespective if the avian N genes carry resistance mutations or not. A range of OE resistance mutations in avian influenza virus have been reported, depending on the geographical location of the bird populations [6,17], but their frequency in influenza viruses circulating in wild birds is overall low . Interestingly, the H274Y resistance mutation was the only one found by Järhult and coworkers in mallards under experimental conditions with environmental OC concentrations , indicating that OC resistance patterns are similar in avian and human influenza H1N1 viruses. However, the present data indicate that the vast majority of H274Y and R292K resistance mutations evolve in the human influenza N1 and N2 genes without involving re-assortment, the major mechanism for exchange of genetic material between influenza viruses , with corresponding avian influenza genes. The low propensity of re-assortment between avian and human N1 viruses observed here is in line with the data by Obenauer et al. . The absence of evidence for homologous recombination between human and avian influenza N1 and N2 genes is in line with previous results that homologous recombination, frequently occurring in DNA viruses , after all is a rare phenomenon in the evolution of influenza and other negative strand viruses, although a few exceptions have been described [21-25].
It cannot be excluded that transfer of resistance mutations from avian influenza N genes ever occur, or that resistance mutations may be transferred and then suppressed below the detection limit due to reduced fitness. However, whereas in case of chronic HIV or hepatitis B virus infection such minor mutant strains may persist even after termination of antiviral treatment, this is unlikely for influenza virus which does not cause chronic infections in humans. Instead, OE antiviral treatment of humans has proven sufficient to induce essentially all OE resistance that has been detected in human influenza until today by selection of mutations within N1 and N2 genes in strains that circulate in humans. Accordingly, the threat to human health from OE resistance emerging as result of treatment of infected humans appears to be much greater than the risk posed by transfer of OC resistance induced in avian influenza virus. This conclusion is not surprising considering the stronger selection pressure for enrichment of resistance mutations in oseltamivir-treated patients with serum OE concentrations of up to 500 μg/L , compared with more moderate concentrations (up to 30 μg/L) that avian influenza viruses encounter in animals close to sewage outlets from waste-water purification plants or adjacent watercourses [4,27,28].
A limitation of the present study is that it includes only avian and human sequences. Thus, we cannot conclude anything about the potential transfer of N genes or resistance mutations between birds and swine. Another limitation is that we have not analyzed OE resistance mutations in non-human influenza virus types such as H5N1, H6N1, H9N2, or H7N2, obtained from humans or birds. Thus, we have not assessed if humans have been infected with avian strains of these types that carry OE resistance induced by environmental exposure. However, these types are dead ends because they cannot be transmitted further to other humans, and the absence of avian clustering among the 17,693 N1 or N2 sequences of human source indicate that transfer of OE resistance by this mechanism is not important. Furthermore, due to the large number of strains, no bootstrapping was included in the phylogenetic analysis. Bootstrapping (bootscan) was, however, included in the recombination analysis performed using the RDP program.
Finally, it is important to stress that pollution of large amounts of oseltamivir or its active metabolic derivatives either as a consequence of manufacture or shedding from treated patients is unsatisfactory from another point of view. The status of OE as a stable, biologically non-degradable compound with the inherent capacity to be enriched in sensitive habitats raises concerns that OE may cause future but as yet unforeseen damage to wildlife in sensitive ecosystems .
Our results presented here demonstrate that transfer of OE resistance mutations from avian to human N genes is extremely rare. It is therefore unlikely that resistance in influenza viruses infecting humans has been transferred from avian avian influenza A virus strains carrying mutations induced by environmental exposure to OC. Instead, resistance in influenza viruses infecting humans is most likely due to the selection pressure posed by the global OE administration in humans.
No patients or persons were included in this study, and accordingly no consents were obtained.
This work was supported by a grant from the Swedish Research Council (Grant 15283).
We also gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database (www.gisaid.org) used in the phylogenetic analysis.
- Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, et al. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza a (H5N1) virus. Lancet Infect Dis. 2007;7(1):21–31.View ArticlePubMedGoogle Scholar
- He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37(6):471–84.View ArticlePubMedGoogle Scholar
- Slater FR, Singer AC, Turner S, Barr JJ, Bond PL. Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug oseltamivir (Tamiflu(R)) and loss of nutrient removal performance. FEMS Microbiol Lett. 2011;315(1):17–22.View ArticlePubMedGoogle Scholar
- Soderstrom H, Jarhult JD, Olsen B, Lindberg RH, Tanaka H, Fick J. Detection of the antiviral drug oseltamivir in aquatic environments. Plos One. 2009;4(6):e6064.View ArticlePubMedPubMed CentralGoogle Scholar
- Ghosh GC, Nakada N, Yamashita N, Tanaka H. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect. 2010;118(1):103–7.PubMedGoogle Scholar
- Orozovic G, Orozovic K, Lennerstrand J, Olsen B. Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds. Plos One. 2011;6(1):e16028.View ArticlePubMedPubMed CentralGoogle Scholar
- Jarhult JD, Muradrasoli S, Wahlgren J, Soderstrom H, Orozovic G, Gunnarsson G, et al. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. Plos One. 2011;6(9):e24742.View ArticlePubMedPubMed CentralGoogle Scholar
- Singer AC, Nunn MA, Gould EA, Johnson AC. Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect. 2007;115(1):102–6.View ArticlePubMedGoogle Scholar
- Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol. 2008;41(1):13–9.View ArticlePubMedGoogle Scholar
- Olofsson S, Kumlin U, Dimmock K, Arnberg N. Avian influenza and sialic acid receptors: more than meets the eye. Lancet Infect Dis. 2005;5:184–8.View ArticlePubMedGoogle Scholar
- Lam TT, Wang J, Shen Y, Zhou B, Duan L, Cheung CL, et al. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature. 2013;502(7470):241–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe. 2010;7(6):440–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Felsenstein J. Phylip. Distributed by the Author. Seattle: Department of Genome Sciences, University of Washington; 2005.Google Scholar
- Bruen TC, Philippe H, Bryant D. A simple and robust statistical test for detecting the presence of recombination. Genetics. 2006;172(4):2665–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Martin DP, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P. RDP3: a flexible and fast computer program for analyzing recombination. Bioinformatics. 2010;26(19):2462–3.View ArticlePubMedPubMed CentralGoogle Scholar
- Hao W. Evidence of intra-segmental homologous recombination in influenza A virus. Gene. 2011;481(2):57–64.View ArticlePubMedGoogle Scholar
- Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, et al. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. J Virol. 2010;84(19):9800–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Philos Trans R Soc Lond B Biol Sci. 2001;356(1416):1861–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Obenauer JC, Denson J, Mehta PK, Su X, Mukatira S, Finkelstein DB, et al. Large-scale sequence analysis of avian influenza isolates. Science. 2006;311(5767):1576–80.View ArticlePubMedGoogle Scholar
- He CQ, Han GZ, Wang D, Liu W, Li GR, Liu XP, et al. Homologous recombination evidence in human and swine influenza A viruses. Virology. 2008;380(1):12–20.View ArticlePubMedGoogle Scholar
- Boni MF, Zhou Y, Taubenberger JK, Holmes EC. Homologous recombination is very rare or absent in human influenza A virus. J Virol. 2008;82(10):4807–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Chare ER, Gould EA, Holmes EC. Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J Gen Virol. 2003;84(Pt 10):2691–703.View ArticlePubMedGoogle Scholar
- Chen Y, Chen YF. Extensive homologous recombination in classical swine fever virus: a re-evaluation of homologous recombination events in the strain AF407339. Saudi J Biol Sci. 2014;21(4):311–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Han GZ, Boni MF, Li SS. No observed effect of homologous recombination on influenza C virus evolution. Virol J. 2010;7:227.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu X, Wu C, Chen AY. Codon usage bias and recombination events for neuraminidase and hemagglutinin genes in Chinese isolates of influenza A virus subtype H9N2. Arch Virol. 2010;155(5):685–93.View ArticlePubMedGoogle Scholar
- McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother. 2001;35(1):57–70.View ArticlePubMedGoogle Scholar
- Ghosh GC, Nakada N, Yamashita N, Tanaka H. Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants. Chemosphere. 2010;81(1):13–7.View ArticlePubMedGoogle Scholar
- Sacca ML, Accinelli C, Fick J, Lindberg R, Olsen B. Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. Chemosphere. 2009;75(1):28–33.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.